The FDA approves new COVID-19 vaccines for 2026, bringing updated protection against the XFG variant currently circulating in the United States. The U.S. Food and Drug Administration granted approvals on August 27 for updated vaccines from Moderna, Pfizer and BioNTech, and Novavax-Sanofi. The vaccines are expected to become available shortly.
The latest approvals are part of the ongoing effort to keep COVID-19 vaccines aligned with changing variants and provide additional protection for people who face a higher risk of serious illness.
Which COVID-19 Vaccines Were Approved?
The FDA approved several updated vaccine options for the 2026 season. These include Moderna’s mNEXSPIKE and Spikevax, Pfizer and BioNTech’s Comirnaty, and Novavax-Sanofi’s Nuvaxovid. The updated formulations are designed to provide protection against the XFG variant.
The availability of multiple vaccines gives eligible individuals and health care providers several options when considering updated COVID-19 vaccination.
Who Should Consider an Updated COVID-19 Vaccine?
The current recommendations highlighted by Forbes focus particularly on people age 65 and older, as well as individuals over six months of age who are immunocompromised. People do not necessarily need documentation proving that they are immunocompromised in order to receive a vaccine.
Family medicine physician David Cutler, M.D., told Forbes that an updated vaccine can provide an additional layer of protection against the circulating strain. Previous infections and vaccinations can also contribute to some cross-immunity, meaning the population generally has more existing protection against severe COVID-19 than it did early in the pandemic.
When Is the Best Time to Get Vaccinated?
Timing can depend on an individual’s health status and likelihood of exposure. Dr. Cutler recommends that people at higher risk, adults over 65 and those facing increased exposure consider an updated vaccine.
He also notes that people who have not had COVID-19 or a COVID-19 vaccination in more than four months may benefit from an updated dose. People who recently had COVID-19 may want to wait, while vaccination timing can also depend on when their previous dose was received.
Unlike influenza vaccination, which is commonly associated with the fall season, COVID-19 exposure can occur throughout the year. As a result, vaccination decisions may be based more on individual exposure and risk than on a single annual vaccination window.
What the New Approval Means
The FDA approves new COVID-19 vaccines as the virus continues to evolve. Updating vaccines for circulating variants is intended to maintain protection as the characteristics of the virus change.
For people who are eligible, an updated vaccine can be another tool for reducing the risk of serious illness. However, individual vaccination decisions should take into account age, medical history, previous infections, previous vaccinations and personal risk factors.
People interested in receiving an updated COVID-19 vaccine can check with pharmacies, clinics or health care providers for availability and appointment options.
The Bottom Line
The latest FDA approvals mark another update in the continuing COVID-19 vaccination effort. With formulations targeting the XFG variant, the new vaccines offer an updated option for people who may benefit from additional protection.
Anyone unsure about whether or when to receive an updated COVID-19 vaccine should speak with a qualified health care professional for guidance based on their individual circumstances.
